GlaxoSmithKline (LSE: GSK) has provided an update on progress at the company’s new manufacturing facility in the South-Indian state of Karnataka.
While the British pharma major had originally planned to open the facility this year, GSK now says the facility will commence production in 2018.
Indian press reports that the company is evaluating new products from its global respiratory and vaccines pipeline for a possible launch in India.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze